OTCMKTS:DSNKY Daiichi Sankyo (DSNKY) Stock Price, News & Analysis → Elon Musk’s Controversial New Project: “Apollo” (From InvestorPlace) (Ad) Free DSNKY Stock Alerts $30.29 +0.17 (+0.56%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$29.18▼$30.3050-Day Range$29.15▼$34.2252-Week Range$23.72▼$37.57Volume78,091 shsAverage Volume134,020 shsMarket CapitalizationN/AP/E Ratio0.26Dividend Yield74.18%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartHeadlinesShort Interest Get Daiichi Sankyo alerts: Email Address Ad InvestorPlaceElon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake. About Daiichi Sankyo Stock (OTCMKTS:DSNKY)Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.Read More DSNKY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DSNKY Stock News HeadlinesMarch 13, 2024 | msn.comMHRA authorises Daiichi Sankyo quizartinib for AML for marketingMarch 2, 2024 | msn.comPfizer, Gilead, Roche seen benefitting the most from antibody-drug conjugatesApril 24, 2024 | InvestorPlace (Ad)Elon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...February 25, 2024 | wsj.comDaiichi Sankyo Co. Ltd. ADRFebruary 19, 2024 | finance.yahoo.comDatopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung CancerFebruary 16, 2024 | morningstar.comDaiichi Sankyo Co Ltd 4568February 16, 2024 | news.yahoo.comDaiichi invests 1 billion eur near Munich to make precision cancer drugsFebruary 16, 2024 | finance.yahoo.comDaiichi invests 1 bln eur near Munich to make precision cancer drugsApril 24, 2024 | InvestorPlace (Ad)Elon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...February 2, 2024 | finance.yahoo.comQ4 2023 Merck & Co Inc Earnings CallJanuary 25, 2024 | msn.comWhat's Going On With Pfizer Stock Today?January 17, 2024 | markets.businessinsider.comUS Patent Office Invalidates Seagen Patent In Daiichi Sankyo Dispute - Quick FactsJanuary 17, 2024 | finance.yahoo.comU.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and SeagenJanuary 3, 2024 | marketwatch.comEsperion Therapeutics, Daiichi Sankyo Europe Reach $125M Payment Agreement Over Commercial LitigationJanuary 3, 2024 | msn.comWhy Pharmaceutical Company Esperion Therapeutics Shares Are Diving TodayDecember 22, 2023 | markets.businessinsider.comMerck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab DeruxtecanDecember 22, 2023 | finance.yahoo.comPatritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung CancerDecember 17, 2023 | msn.comDaiichi Sankyo Co., - ADR (DSNKY) Price Target Increased by 8.80% to 38.57December 12, 2023 | businesswire.comDepixus Announces Strategic Collaboration With Daiichi Sankyo to Use MAGNA™ Technology to Accelerate RNA-targeted Drug DiscoveryDecember 1, 2023 | baystreet.ca300,000 New Cases: The Role of Biotech in Addressing Rising Breast Cancer RatesDecember 1, 2023 | businesswire.comDaiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASHNovember 27, 2023 | finance.yahoo.comJapan panel recommends approval of updated Daiichi Sankyo COVID shot- KyodoOctober 31, 2023 | investing.comDaiichi Sankyo Co., Ltd. (4568)October 31, 2023 | finance.yahoo.comMerck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?October 26, 2023 | finance.yahoo.comMerck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts SalesOctober 26, 2023 | finance.yahoo.com‘Guided Missile Drugs’ Could Be Big Pharma’s Secret WeaponOctober 23, 2023 | bloomberg.comMerck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo DealSee More Headlines Receive DSNKY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daiichi Sankyo and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - General Sub-IndustryN/A Current SymbolOTCMKTS:DSNKY CUSIPN/A CIKN/A Webwww.daiichisankyo.com Phone(136) 225-1111FaxN/AEmployees17,435Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.26 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Sunao Manabe D.V.M. (Age 70)Ph.D., Group CEO & Executive Chairperson Comp: $1.82MMr. Hiroyuki Okuzawa (Age 62)President, COO & Representative Director Comp: $713.24kMr. Masahiko Ohtsuki (Age 65)Senior Managing Exec. Officer, Head of Global DX, Chief Digital Transformation Officer & Director Comp: $713.24kDr. Shoji Hirashima (Age 63)Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director Comp: $771.6kMr. Koji OgawaManaging Executive Officer, Head of Global Corporate Planning & Management and CFOChiyuGeneral Manager of Finance & Accounting DepartmentHiroto KashiwaseManaging Executive Officer, Head of Technology Management HQ and Head of Supply Chain HQNaoto TsukaguchiGen. Counsel, Corp. Officer, Head of Global Leg., IP, Global Compl. and Risk & VP of Leg. Aff. Dept.Kentaro AsakuraVice President of Corporate Communications DepartmentMs. Marielle Cohard-Radice M.D.Global Head of DevelopmentMore ExecutivesKey CompetitorsAstraZenecaOTCMKTS:AZNCFCosmo PharmaceuticalsOTC:CMOPFCSPC Pharmaceutical GroupOTCMKTS:CSPCYDechra PharmaceuticalsOTCMKTS:DCHPFJCR PharmaceuticalsOTCMKTS:JCRRFView All Competitors DSNKY Stock Analysis - Frequently Asked Questions Should I buy or sell Daiichi Sankyo stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daiichi Sankyo in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" DSNKY shares. View DSNKY analyst ratings or view top-rated stocks. How have DSNKY shares performed in 2024? Daiichi Sankyo's stock was trading at $27.35 on January 1st, 2024. Since then, DSNKY shares have increased by 10.7% and is now trading at $30.29. View the best growth stocks for 2024 here. Are investors shorting Daiichi Sankyo? Daiichi Sankyo saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 37,900 shares, an increase of 176.6% from the March 15th total of 13,700 shares. Based on an average daily trading volume, of 265,400 shares, the days-to-cover ratio is currently 0.1 days. View Daiichi Sankyo's Short Interest. Is Daiichi Sankyo a good dividend stock? Daiichi Sankyo (OTCMKTS:DSNKY) pays an annual dividend of $22.47 per share and currently has a dividend yield of 3.12%. The dividend payout ratio is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%. How do I buy shares of Daiichi Sankyo? Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:DSNKY) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryBiden out June 13; Kamala won’t replace him?Paradigm PressThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daiichi Sankyo Company, Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
